NCT03796039 is a NA clinical trial of Standing in Frailty, sponsored by University of New Brunswick.

Who is sponsoring NCT03796039?

NCT03796039 is sponsored by University of New Brunswick.

What drugs are being tested in NCT03796039?

Interventions in NCT03796039: Standing.

What condition does NCT03796039 study?

NCT03796039 studies Frailty, Sedentary Behavior, Physical Disability.

Is NCT03796039 still recruiting?

NCT03796039 is currently completed. Last updated 27 June 2023.

Are results published for NCT03796039?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-06-27 · How we verify

NCT03796039

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stand if You Can: A Standing Intervention in Long Term Care

Completed NA Results posted Last updated 27 June 2023

What this trial tests

NA trial testing Standing in Frailty in 97 participants. Completed in 15 July 2020.

Timeline

1 April 2019

Primary endpoint
23 January 2020

15 July 2020

Quick facts

Lead sponsor	University of New Brunswick
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	97
Start date	1 April 2019
Primary completion	23 January 2020
Estimated completion	15 July 2020
Sites	1 location across Canada

Drugs / interventions tested

Standing

Conditions studied

Frailty — all drugs for Frailty →
Sedentary Behavior — all drugs for Sedentary Behavior →
Physical Disability — all drugs for Physical Disability →

Sponsor

University of New Brunswick

Who can join

Eligibility, any sex, with Frailty or Sedentary Behavior. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Changes in Walking Speed Primary · Pre and post intervention testing

Measured by the 10m walking speed test

Pre

Group	Value	95% CI
Standing and Social Intervention	0.34	± 0.17
Control Group	0.43	± 0.20

Post

Group	Value	95% CI
Standing and Social Intervention	0.35	± 0.20
Control Group	0.40	± 0.20

Change in Leg Strength Secondary · Pre-Post Testing (following the 5 month intervention)

Using hand-held dynamometer to quantify leg strength through knee extension

Pre

Group	Value	95% CI
Standing and Social Intervention	9.48	± 5.95
Control Group	7.87	± 5.42

Post

Group	Value	95% CI
Standing and Social Intervention	9.15	± 5.25
Control Group	7.28	± 4.90

Change Lower Limb Power Secondary · Pre-Post Testing (following the 5 month intervention)

Using the 30second sit-stand test following senior fitness test protocol

Pre

Group	Value	95% CI
Standing and Social Intervention	0.74	± 1.84
Control Group	0.89	± 2.34

Post

Group	Value	95% CI
Standing and Social Intervention	0.71	± 1.81
Control Group	1.1	± 2.82

Change in Anxiety Symptoms Secondary · Pre-Post Testing (following the 5 month intervention)

The Geriatric Anxiety Inventory (Scale 0-20). A low score means a better outcome.

Pre

Group	Value	95% CI
Standing and Social Intervention	6.1	± 7.2
Control Group	6.6	± 6.0

Post

Group	Value	95% CI
Standing and Social Intervention	6.7	± 7.1
Control Group	6.6	± 6.1

Depression Secondary · Pre-Post Testing (following the 5 month intervention)

Geriatric Depression Scale Short Form (0-15 scale). Lower score is better outcome.

Pre

Group	Value	95% CI
Standing and Social Intervention	5.1	± 3.2
Control Group	4.9	± 3.5

Post

Group	Value	95% CI
Standing and Social Intervention	5.5	± 4.0
Control Group	4.5	± 2.9

Loneliness Secondary · Pre-Post Testing (following the 5 month intervention)

Loneliness was measured using the UCLA Loneliness Scale (20-80). A low score indicates a better outcome

Pre

Group	Value	95% CI
Standing and Social Intervention	42.3	± 12.0
Control Group	39.7	± 12.6

Post

Group	Value	95% CI
Standing and Social Intervention	38.7	± 12.4
Control Group	33.8	± 11.2

Fall Efficacy Secondary · Pre-Post Testing (following the 5 month intervention)

Falls Efficacy Scale-International Questionnaire (16-64 scale). Low score indicates a better score

Pre

Group	Value	95% CI
Standing and Social Intervention	36.7	± 13.2
Control Group	31.0	± 12.8

Post

Group	Value	95% CI
Standing and Social Intervention	41.3	± 17.4
Control Group	39.0	± 11.8

Metabolic Profile - Triglycerides Secondary · Pre-Post Testing (before and following the 5 month intervention).

Capillary blood analyzed with a cardiochek device. Blood collected via a finger prick and analyzed with a cardiochek device. Note that Total Cholesterol, HDL, Triglycerides, LDL and Glucose were all measured using the cardiochek device.

Pre

Group	Value	95% CI
Standing and Social Intervention	1.79	± 1.30
Control Group	1.21	± 0.45

Post

Group	Value	95% CI
Standing and Social Intervention	1.48	± 0.74
Control Group	1.47	± 0.82

Metabolic Profile - High Density Lipoprotein Cholesterol Secondary · Pre and post testing (before and after the 5-month intervention)

High Density Lipoprotein (HDL) cholesterol was analyzed using the CardioChek Professional Analyzer system (PTS Diagnostics, Whitestown, Indiana, USA). A finger prick was conducted using a single use lancet and approximately 60 µL of whole blood was collected for this test.

Pre

Group	Value	95% CI
Standing and Social Intervention	1.37	± 1.52
Control Group	1.33	± 0.51

Post

Group	Value	95% CI
Standing and Social Intervention	1.27	± 0.44
Control Group	1.17	± 0.57

Metabolic Profile - Low Density Lipoprotein Cholesterol Secondary · Pre-Post intervention (before and after 5-month intervention)

Low-density lipoprotein was assessed using a CardioChek Professional Analyzer system (PTS Diagnostics, Whitestown, Indiana, USA).

Pre

Group	Value	95% CI
Standing and Social Intervention	2.40	± 1.63
Control Group	2.91	± 1.42

Post

Group	Value	95% CI
Standing and Social Intervention	2.19	± 1.21
Control Group	2.72	± 1.56

Metabolic Profile - Blood Glucose Secondary · Pre-Post Intervention (before and after 5-month intervention)

Fasted blood glucose was analyzed using a CardioChek Professional Analyzer system (PTS Diagnostics, Whitestown, Indiana, USA).

Pre

Group	Value	95% CI
Standing and Social Intervention	5.96	± 2.38
Control Group	5.43	± 1.95

Post

Group	Value	95% CI
Standing and Social Intervention	6.08	± 2.29
Control Group	5.47	± 1.77

Adverse events — posted to ClinicalTrials.gov

Time frame: During trial (5 months). Reporting threshold: 2%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Standing and Social Intervention

Serious: 0/50 (0%)

Deaths: 0/50

Control Group

Serious: 0/47 (0%)

Deaths: 0/47

Other adverse events (1 terms — click to expand)

Reaction	System	Standing and Social Interv…	Control Group
Fall	Injury, poisoning and procedural complications	—	—

Data from ClinicalTrials.gov NCT03796039 adverse events section.

Sponsor's own description

It is currently unknown if reducing sitting time, an activity that is highly prevalent in frail older adults living in long term care (LTC) facilities, is associated with an improvement in physical capacity such as walking speed. Simple tasks such as walking speed is associated with important outcomes for residents in LTC such as autonomy and hospitalization. The investigators hypothesize that standing an additional 100 minutes per week for 5 months will result in a clinically meaningful improvement in walking speed (0.1m/sec) in LTC residents compared to residents receiving a sitting social activity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Stand if you can- A parallel, superiority cluster randomized controlled trial to improve gait speed for long term care residents.
Cooling K, Bouchard DR, Gallibois M, Hebert J, et al · · 2025 · PMID 40469490 · DOI 10.1016/j.jarlif.2025.100015

Verify or expand the search:

Other trials of Standing

Trials testing the same drug.

NCT06963736 — WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time · NA · recruiting
NCT04389736 — Effects of NMES on Energy Expenditure, Glycaemia and Hormonal Responses to Glucose Ingestion · NA · completed
NCT03602482 — Standing Cognition and Co-morbidities of POTS Evaluation · NA · completed
NCT03213717 — Effect of Body Weight Loading on Urinary Electrolyte Excretion · NA · completed

Other recruiting trials for Frailty

Currently open trials in the same condition.

NCT07481188 — Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery · recruiting
NCT07519603 — Frailty in Older Adults With Chronic Obstructive Pulmonary Disease (COPD) and Outcomes of the VIVIFRAIL Program · NA · recruiting
NCT07144527 — Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults · NA · recruiting
NCT07392944 — Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Home · NA · recruiting
NCT07475767 — Ultrasound Indicators of Nutritional Status and Treatment Outcomes in Surgical Patients in the Intensive Care Unit · recruiting

Other University of New Brunswick trials

Trials by the same sponsor.

NCT07309536 — Mediterranean Diet Uptake and Nutrition on Child Health, Inflammation, and Early-life Symbiosis (MUNCHIES) Study · NA · not yet recruiting
NCT06285786 — Patient Handling Techniques and New Technology for Health Care Workers · NA · unknown
NCT05385458 — Acceptance and Commitment Therapy (ACT) Tele-Counselling · NA · completed
NCT05615831 — The Impact of Exercise With Blood Flow Restriction: Sex and Age Differences · NA · completed
NCT04997681 — SYNchronizing Exercises, Remedies in Gait and Cognition at Home (SYNERGIC@Home) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03796039 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of New Brunswick
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03796039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03796039

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Standing

Other recruiting trials for Frailty

Other University of New Brunswick trials

Verify against primary sources